SCHEMBL6539121

SCHEMBL6539121

COc1ccc(-c2[nH]c(=O)ccc2-c2ccc(=O)n(C(C)C)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 8/20 0.45
LMNA P02545 1/20 0.42
HRH3 Q9Y5N1 2/20 0.39
TDP1 Q9NUW8 1/20 0.38
ATM Q13315 1/20 0.38
MAP2K1 Q02750 1/20 0.37
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
ADORA3 P0DMS8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6539134 0.87 BRD4 (0.39) PDE10ALMNA
SCHEMBL6538527 0.86 PDE10A (0.40) PDE10AHRH3HTR2AHTR2CHTR2B
SCHEMBL6538758 0.85 PDE10A (0.38) PDE10AKDM4EPOLB
SCHEMBL6538043 0.82 CDK4 (0.39) LMNAHRH3TDP1ATMKDM4E
SCHEMBL6538769 0.81 PDE1A (0.39) KDM4E
SCHEMBL6538958 0.75 HCAR1 (0.32) PDE10AHRH3
SCHEMBL5904146 0.75 PDE10A (0.60) PDE10ALMNATDP1MAP2K1KDM4E
SCHEMBL6133595 0.72 KMT2A (0.58) LMNAHRH3KDM4ETSHR
SCHEMBL6539735 0.71 HTR2A (0.41) LMNAHRH3TDP1ATMKDM4E
SCHEMBL6538812 0.71 SERPINE1 (0.42) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 PDE10A 132/4885LMNA 1052/4885HRH3 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.